A case of recalcitrant chronic urticaria successfully controlled by warfarin

Eriko Maehara, Chikage Mitoma, Hiroko Takamatsu, Kayo Harada, Naoko Wada, Tomoyo Matsuda, Noriko Ishida, Shuhei Imayama, Kazunori Urabe

Research output: Contribution to journalArticle

Abstract

We describe a case of recalcitrant chronic urticaria successfully controlled by warfarin. A 53-year-old female had suffered from urticaria and angioedema for 6 months. She had been treated with antihistamines, H2-receptor antagonist, leukotriene receptor antagonist, diaminodiphenyl sulfone, prednisolone, and cyclosporine; however, no medicine suppressed the urticaria. Previous reports have demonstrated that thrombin protein synthesis is enhanced in patients with chronic urticaria. Moreover, warfarin, which inhibits the synthesis of thrombin and coagulation proteins, has been reported to suppress urticaria. Based on these findings, the patient was administered 1 mg per day of warfarin in addition to cyclosporine, olopatadine, and the H2-blocker famotidine. Three days later, the dose of warfarin was increased from 1 to 2 mg per day, and it was subsequently increased by 1 mg every week. The prothrombin time international normalized ratio (PTINR) was maintained at around 1. 3 when she was administered 4 mg per day of warfarin. At the start of warfarin administration, the UAS7 score, which was originally defined at our institute, was 42 points. Notably, the UAS7 decreased to 7 points 25 days later, upon the administration of 4 mg per day of warfarin. Subsequently, this score dropped to 0. Cyclosporine was discontinued at the 30th week, and subsequently warfarin was stopped at the 50th week, followed by the discontinuation of famotidine and olopatadine. During 14 months after the end of the treatment, there was no relapse of any symptoms, such as itching, erythema, or wheals. The present case report demonstrates the effectiveness of warfarin treatment for recalcitrant chronic urticaria.

Original languageEnglish
Pages (from-to)15-19
Number of pages5
JournalNishinihon Journal of Dermatology
Volume80
Issue number1
DOIs
Publication statusPublished - Jan 1 2018

Fingerprint

Urticaria
Warfarin
Cyclosporine
Famotidine
Thrombin
Leukotriene Antagonists
Angioedema
Histamine H2 Receptors
Sulfones
International Normalized Ratio
Histamine Antagonists
Prothrombin Time
Erythema
Pruritus
Prednisolone
Proteins
Medicine
Recurrence

All Science Journal Classification (ASJC) codes

  • Dermatology

Cite this

Maehara, E., Mitoma, C., Takamatsu, H., Harada, K., Wada, N., Matsuda, T., ... Urabe, K. (2018). A case of recalcitrant chronic urticaria successfully controlled by warfarin. Nishinihon Journal of Dermatology, 80(1), 15-19. https://doi.org/10.2336/nishinihonhifu.80.15

A case of recalcitrant chronic urticaria successfully controlled by warfarin. / Maehara, Eriko; Mitoma, Chikage; Takamatsu, Hiroko; Harada, Kayo; Wada, Naoko; Matsuda, Tomoyo; Ishida, Noriko; Imayama, Shuhei; Urabe, Kazunori.

In: Nishinihon Journal of Dermatology, Vol. 80, No. 1, 01.01.2018, p. 15-19.

Research output: Contribution to journalArticle

Maehara, E, Mitoma, C, Takamatsu, H, Harada, K, Wada, N, Matsuda, T, Ishida, N, Imayama, S & Urabe, K 2018, 'A case of recalcitrant chronic urticaria successfully controlled by warfarin', Nishinihon Journal of Dermatology, vol. 80, no. 1, pp. 15-19. https://doi.org/10.2336/nishinihonhifu.80.15
Maehara, Eriko ; Mitoma, Chikage ; Takamatsu, Hiroko ; Harada, Kayo ; Wada, Naoko ; Matsuda, Tomoyo ; Ishida, Noriko ; Imayama, Shuhei ; Urabe, Kazunori. / A case of recalcitrant chronic urticaria successfully controlled by warfarin. In: Nishinihon Journal of Dermatology. 2018 ; Vol. 80, No. 1. pp. 15-19.
@article{61ea857703e64176af4773f1fe396dde,
title = "A case of recalcitrant chronic urticaria successfully controlled by warfarin",
abstract = "We describe a case of recalcitrant chronic urticaria successfully controlled by warfarin. A 53-year-old female had suffered from urticaria and angioedema for 6 months. She had been treated with antihistamines, H2-receptor antagonist, leukotriene receptor antagonist, diaminodiphenyl sulfone, prednisolone, and cyclosporine; however, no medicine suppressed the urticaria. Previous reports have demonstrated that thrombin protein synthesis is enhanced in patients with chronic urticaria. Moreover, warfarin, which inhibits the synthesis of thrombin and coagulation proteins, has been reported to suppress urticaria. Based on these findings, the patient was administered 1 mg per day of warfarin in addition to cyclosporine, olopatadine, and the H2-blocker famotidine. Three days later, the dose of warfarin was increased from 1 to 2 mg per day, and it was subsequently increased by 1 mg every week. The prothrombin time international normalized ratio (PTINR) was maintained at around 1. 3 when she was administered 4 mg per day of warfarin. At the start of warfarin administration, the UAS7 score, which was originally defined at our institute, was 42 points. Notably, the UAS7 decreased to 7 points 25 days later, upon the administration of 4 mg per day of warfarin. Subsequently, this score dropped to 0. Cyclosporine was discontinued at the 30th week, and subsequently warfarin was stopped at the 50th week, followed by the discontinuation of famotidine and olopatadine. During 14 months after the end of the treatment, there was no relapse of any symptoms, such as itching, erythema, or wheals. The present case report demonstrates the effectiveness of warfarin treatment for recalcitrant chronic urticaria.",
author = "Eriko Maehara and Chikage Mitoma and Hiroko Takamatsu and Kayo Harada and Naoko Wada and Tomoyo Matsuda and Noriko Ishida and Shuhei Imayama and Kazunori Urabe",
year = "2018",
month = "1",
day = "1",
doi = "10.2336/nishinihonhifu.80.15",
language = "English",
volume = "80",
pages = "15--19",
journal = "Nishinihon Journal of Dermatology",
issn = "0386-9784",
publisher = "Kyushu University, Faculty of Science",
number = "1",

}

TY - JOUR

T1 - A case of recalcitrant chronic urticaria successfully controlled by warfarin

AU - Maehara, Eriko

AU - Mitoma, Chikage

AU - Takamatsu, Hiroko

AU - Harada, Kayo

AU - Wada, Naoko

AU - Matsuda, Tomoyo

AU - Ishida, Noriko

AU - Imayama, Shuhei

AU - Urabe, Kazunori

PY - 2018/1/1

Y1 - 2018/1/1

N2 - We describe a case of recalcitrant chronic urticaria successfully controlled by warfarin. A 53-year-old female had suffered from urticaria and angioedema for 6 months. She had been treated with antihistamines, H2-receptor antagonist, leukotriene receptor antagonist, diaminodiphenyl sulfone, prednisolone, and cyclosporine; however, no medicine suppressed the urticaria. Previous reports have demonstrated that thrombin protein synthesis is enhanced in patients with chronic urticaria. Moreover, warfarin, which inhibits the synthesis of thrombin and coagulation proteins, has been reported to suppress urticaria. Based on these findings, the patient was administered 1 mg per day of warfarin in addition to cyclosporine, olopatadine, and the H2-blocker famotidine. Three days later, the dose of warfarin was increased from 1 to 2 mg per day, and it was subsequently increased by 1 mg every week. The prothrombin time international normalized ratio (PTINR) was maintained at around 1. 3 when she was administered 4 mg per day of warfarin. At the start of warfarin administration, the UAS7 score, which was originally defined at our institute, was 42 points. Notably, the UAS7 decreased to 7 points 25 days later, upon the administration of 4 mg per day of warfarin. Subsequently, this score dropped to 0. Cyclosporine was discontinued at the 30th week, and subsequently warfarin was stopped at the 50th week, followed by the discontinuation of famotidine and olopatadine. During 14 months after the end of the treatment, there was no relapse of any symptoms, such as itching, erythema, or wheals. The present case report demonstrates the effectiveness of warfarin treatment for recalcitrant chronic urticaria.

AB - We describe a case of recalcitrant chronic urticaria successfully controlled by warfarin. A 53-year-old female had suffered from urticaria and angioedema for 6 months. She had been treated with antihistamines, H2-receptor antagonist, leukotriene receptor antagonist, diaminodiphenyl sulfone, prednisolone, and cyclosporine; however, no medicine suppressed the urticaria. Previous reports have demonstrated that thrombin protein synthesis is enhanced in patients with chronic urticaria. Moreover, warfarin, which inhibits the synthesis of thrombin and coagulation proteins, has been reported to suppress urticaria. Based on these findings, the patient was administered 1 mg per day of warfarin in addition to cyclosporine, olopatadine, and the H2-blocker famotidine. Three days later, the dose of warfarin was increased from 1 to 2 mg per day, and it was subsequently increased by 1 mg every week. The prothrombin time international normalized ratio (PTINR) was maintained at around 1. 3 when she was administered 4 mg per day of warfarin. At the start of warfarin administration, the UAS7 score, which was originally defined at our institute, was 42 points. Notably, the UAS7 decreased to 7 points 25 days later, upon the administration of 4 mg per day of warfarin. Subsequently, this score dropped to 0. Cyclosporine was discontinued at the 30th week, and subsequently warfarin was stopped at the 50th week, followed by the discontinuation of famotidine and olopatadine. During 14 months after the end of the treatment, there was no relapse of any symptoms, such as itching, erythema, or wheals. The present case report demonstrates the effectiveness of warfarin treatment for recalcitrant chronic urticaria.

UR - http://www.scopus.com/inward/record.url?scp=85048566516&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048566516&partnerID=8YFLogxK

U2 - 10.2336/nishinihonhifu.80.15

DO - 10.2336/nishinihonhifu.80.15

M3 - Article

AN - SCOPUS:85048566516

VL - 80

SP - 15

EP - 19

JO - Nishinihon Journal of Dermatology

JF - Nishinihon Journal of Dermatology

SN - 0386-9784

IS - 1

ER -